Who
nancy lynn snyderman
Director
Company insider
Files Form 4 as: Director, Alkermes; Director, Lyra Therapeutics; Director, Axonics; Director, Future Health ESG.
In numbers
- Trades disclosed
- 89
- Buys
- 3
- Sells
- 1
- Bought
- $94K
- Sold
- $4.5M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 14 Sep 2016
- Last trade
- 3 Aug 2026
- Last filed
- 3 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $1.3M27,948 at $46.72 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $772K16,524 at $46.72 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $2.2M44,472 at $50.35 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,948 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —16,524 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,948 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —16,524 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $1.3M27,948 at $46.72 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $772K16,524 at $46.72 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $2.2M44,472 at $50.35 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $55K1,475 at $36.95 | filing |
| 21 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $55K1,475 at $36.95 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
News
Financial Survey: INmune Bio (NASDAQ:INMB) vs. Alkermes (NASDAQ:ALKS)ALKS · themarketsdaily.com · 20 Oct 2026Traders Buy High Volume of Put Options on Alkermes (NASDAQ:ALKS)ALKS · tickerreport.com · 17 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)ALKS · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name nancy lynn snyderman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.